Investigating the effect of rosuvastatin in patients with human immunodeficiency virus (HIV)

Investigating the immunological effect of rosuvastatin in patients with human immunodeficiency virus (HIV) with adequate virological response and no immunological response

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231124060158N1

Enrollment

Registered

2023-12-08

Start date

2019-08-31

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with human immunodeficiency virus. Acquired immunodeficiency syndrome [AIDS] NOSAIDS-related complex [ARC] NOS

Interventions

Intervention group:.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Lack of immunological response, suitable virological response receiving rosuvastatin treatment willingness of the patient to cooperate in the study and fill in the informed consent form - HIV infection age at least 18 years

Exclusion criteria

Exclusion criteria: Patients' lack of consent to participate in the study Non-cooperation of patients Lack of adequate virologic response Having an immunological response

Design outcomes

Primary

Measure	Time frame
Determining the immunological effect of statin in HIV+ patients with adequate virological response and no immunological response. Timepoint: The effect of rosuvastatin in patients after 90 days and based on CD4 measured before and after the treatment is determined and compared in patients based on other variables. Method of measurement: Measurement of CD4 before and after treatment through patients' blood samples.	—

Measure

Time frame

Determining the immunological effect of statin in HIV+ patients with adequate virological response and no immunological response. Timepoint: The effect of rosuvastatin in patients after 90 days and based on CD4 measured before and after the treatment is determined and compared in patients based on other variables. Method of measurement: Measurement of CD4 before and after treatment through patients' blood samples.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactsaeed kalantari

Iran University of Medical Sciences

dr.saeed.kalantari@gmail.com+98 21 4487 8404

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026